← 홈

전체 프로그램

ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 1,486개
AntibodyTracon Pharmaceuticals Inc.Phase 2

Androgen receptor inhibitor (Androgen receptor inhibitor)

Prostate Cancer · Prostate Cancer

#ProstateCancer#Antibody#Phase2#인기#항체+4
임상시험 54상태 RECRUITING
CGTBiologicShenzhen Hornetcorn Bio-technol…Preclinical

CIK cell therapy (CIK cell therapy)

Non Small Cell Lung Cancer · Non Small Cell Lung Cancer

#NonSmallCellLungCancer#CGT#Preclinical#인기#세포유전치료+4
임상시험 54상태 ACTIVE
ADCBiologicAstraZenecaPhase 2

Cediranib (Cediranib)

Non-Small Cell Lung Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#ADC#Phase2#인기#항체약물접합체+3
효능 ORR 26%임상시험 54상태 RECRUITING
ADCBiologicPfizerPhase 3

Docetaxel monotherapy (Docetaxel monotherapy)

Non-small Cell Carcinoma; Non-Small Cell Lung Cancer Metastatic · Non-small Cell Carcinoma

#Non-smallCellCarcinoma#ADC#Phase3#인기#항체약물접합체+3
효능 ORR 95%임상시험 54상태 RECRUITING
ADCBiologicFondazione per la Medicina Pers…calicheamicin-based antibod…Phase 2

Ponatinib (Ponatinib)

Breast Cancer; Gastrointestinal Cancer · FRα

#FR#ADC#Phase2#인기#항체약물접합체+5
효능 ORR 7.1%임상시험 54상태 ACTIVE
ADCBiologicSeagen Inc.deruxtecan and tucatinibPhase 1

ONT-380 (Tucatinib, Tucatinib (ONT-380))

HER2 Positive Breast Cancers · HER2

#HER2#ADC#Phase1#인기#항체약물접합체+5
효능 ORR 100%임상시험 54상태 ACTIVE
CGTBiologicNovartis PharmaceuticalsPhase 2

cytogenetic analysis (cytogenetic analysis)

Chronic Myeloproliferative Disorders; Leukemia · Colorectal Cancer

#ColorectalCancer#CGT#Phase2#인기#세포유전치료+5
임상시험 54상태 ACTIVE
ADCBiologicQuantumLeap Healthcare Collabor…Phase 2

ABT-888 (ABT-888)

Breast Neoplasms; Breast Cancer · HER2

#HER2#ADC#Phase2#인기#항체약물접합체+4
효능 ORR 74.1%임상시험 53상태 RECRUITING
AntibodyRocheVedotin on Brain Metastases…Phase 2

atezolizumab (Tecentriq, Atezolizumab - 28 Day Cycle)

Endometrial Cancer · Endometrial Cancer

#EndometrialCancer#Antibody#Phase2#인기#항체+5
효능 ORR 90%임상시험 53상태 RECRUITING
ADCBiologicJiangsu HengRui Medicine Co., L…Phase 2

Famitinib (Famitinib)

Advanced Breast Cancer; Metastatic Breast Cancer · HER2

#HER2#ADC#Phase2#인기#항체약물접합체+5
임상시험 53상태 RECRUITING
ADCBiologicAdenoid Cystic Carcinoma Resear…Phase 1

IMD (Implantable Microdevice, Implantable Microdevice (IMD))

Triple Negative Breast Cancer; Breast Cancer Stage II · Triple Negative Breast Cancer

#TripleNegativeBreastCancer#ADC#Phase1#인기#항체약물접합체+3
효능 ORR 0.1%임상시험 53상태 DISCONTINUED
ADCBiologicFudan UniversityderuxtecanPhase 2

Dalpiciclib (Dalpiciclib)

HER2-positive Breast Cancer · HER2

#HER2#ADC#Phase2#인기#항체약물접합체+4
임상시험 52상태 RECRUITING
Antibody3D Medicines (Sichuan) Co., Ltd.Phase 2

Envafolimab (Envafolimab)

Prostate Cancer; CDK12 Gene Mutation · Prostate Cancer

#ProstateCancer#Antibody#Phase2#인기#항체+5
임상시험 52상태 RECRUITING
ADCBiologicSWOG Cancer Research NetworkVedotin, and BelinostatPhase 3

Pirtobrutinib (Pirtobrutinib)

Richter Syndrome; Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma · Chronic Lymphocytic Leukemia

#ChronicLymphocyticLeukemia#ADC#Phase3#인기#항체약물접합체+5
효능 ORR 66.4%임상시험 52상태 RECRUITING
ADCBiologicPfizerderuxtecan have preventive …Phase 2

lorlatinib (lorlatinib)

Non-Small Cell Lung Cancer · Cancer

#Cancer#ADC#Phase2#인기#항체약물접합체+5
효능 ORR 75.8%임상시험 52상태 DISCONTINUED
AntibodyJanssenderuxtecan, datopotamab der…Phase 3

Amivantamab (Amivantamab)

Carcinoma, Non-Small-Cell Lung · Colorectal Cancer

#ColorectalCancer#Antibody#Phase3#인기#항체+5
효능 ORR 4.3%임상시험 51상태 RECRUITING
AntibodyRegeneronPhase 2

Cemiplimab REGN2810 (Cemiplimab REGN2810)

Plasma Cell Myeloma · Prostate Cancer

#ProstateCancer#Antibody#Phase2#인기#항체+5
효능 ORR 55.6%임상시험 51상태 ACTIVE
ADCBiologicUNICANCERPhase 2

Copanlisib (Copanlisib)

Carcinoma, Squamous Cell of Head and Neck · FRα

#FR#ADC#Phase2#인기#항체약물접합체+5
효능 ORR 100%임상시험 51상태 DISCONTINUED
ADCBiologicAmgenbiodistributionPhase 2

Sotorasib (Sotorasib)

Colorectal Cancer; Resectable Colorectal Carcinoma · Locally Advanced Lung Non-Small Cell Car

#LocallyAdvancedLungNon-SmallCell#ADC#Phase2#인기#항체약물접합체+5
효능 ORR 0%임상시험 51상태 RECRUITING
ADCBiologicAstraZenecaderuxtecan or sacituzumab g…Phase 2

Capivasertib (Capivasertib)

Metastatic Breast Cancer · FRα

#FR#ADC#Phase2#인기#항체약물접합체+5
효능 ORR 56.5%임상시험 50상태 RECRUITING

9 / 75 페이지

← 이전다음 →